A global health organisation and state-of-the-art laboratory at The University of Queensland are collaborating to support the development and evaluation of point-of-care diagnostics for malaria with new custom-made proteins.
PATH and UQ’s Protein Expression Facility will supply researchers with malaria proteins to improve point-of-care diagnostic tools and help reduce the burden of malaria, which continues to affect more than 200 million people and cause more than 400,000 deaths each year.
Director of UQ’s Protein Expression Facility Professor Linda Lua said the partnership would help malaria researchers develop new diagnostic tools.
“New tools to enable the development of highly sensitive diagnostics are urgently needed to reduce disease and death attributable to malaria,” Professor Lua said.
“PATH and UQ are pleased to announce the availability of highly specific and sensitive malaria antigen reagents for immunological tests.
“These custom proteins will facilitate the development and performance benchmarking of rapid, accurate and species-specific malaria diagnostics.
“The collaboration between PATH and UQ’s Protein Expression Facility to develop and commercialise highly specific and sensitive Plasmodium antigens for immunological tests will help developers, manufacturers and academic researchers to assess the reliability of malaria test results.”
Most life-threatening malaria cases are attributable to infection with Plasmodium falciparum parasites which causes liver and kidney failure, convulsions, and coma.
Professor Lua said there was an urgent need to develop diagnostic methods that are simple, sensitive, and Plasmodium species specific to treat people with mixed parasitical infections.
Senior Scientific Director and malaria diagnostics lead in the Diagnostics Program at PATH, Dr Gonzalo Domingo, said the accurate and rapid diagnosis of species-specific malaria infection presented a challenge in most countries where the disease was endemic.
“We are excited in our collaboration with The University of Queensland to provide custom malaria proteins that support the development of simple, sensitive immunological tests that are able to quickly and accurately differentiate Plasmodium species,” Dr Domingo said.
In PATH’s role as a catalytic product development partner, PATH hopes that the availability of these proteins will de-risk and incentivise diagnostic researchers and manufacturers in developing more appropriate rapid diagnostic tests for malaria.
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.